BRLS

Borealis is operationally improving but financially at the edge of a cliff, and the balance sheet — not the P&L — is what governs this stock. The auditors have issued an explicit going-concern paragraph for FY2025 and FY2024, citing recurring losses, negative operating cash flow (-$6.60M), a working capital deficit of ~$61.8M, and cash of just $0.06M. Stockholders' equity is negative at -$19.2M against $71.8M of liabilities (a -3.73x liabilities/equity that is meaningless except as a signal of insolvency), and current liabilities of $69.8M dwarf current assets of $8.06M. With $64K of cash on hand, the company cannot self-fund; survival depends entirely on outside capital, and management says so directly.

The operating story is genuinely better year over year — revenue +8.2% to $31.5M, gross profit +60.4% to $3.51M (11.2% margin), SG&A down sharply, and the net loss narrowing to -$19.0M — and management frames the loss as 'the lingering burden of a capital structure shaped by the 2024 Reverse Recapitalization, not operational underperformance.' That may be fair, but at an 11.2% gross margin and a -35.1% operating margin, the improving trajectory is nowhere near the scale needed to service substantial debt, let alone reach self-sustaining cash flow. R&D at $202K is negligible, so the 'food science' moat is thin in the numbers.